Massachusetts Financial Services CO Vir Biotechnology, Inc. Transaction History

Massachusetts Financial Services CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$9.14 - $24.62 $22,091 - $59,506	-2,417 Reduced 3.69%	63,057 $590,000
Q2 2023 Aug 09, 2023	SELL	$23.2 - $27.29 $35,774 - $42,081	-1,542 Reduced 2.3%	65,474 $1.61 Million
Q1 2023 May 10, 2023	SELL	$22.26 - $30.85 $889,242 - $1.23 Million	-39,948 Reduced 37.35%	67,016 $1.56 Million
Q4 2022 Feb 13, 2023	BUY	$19.96 - $28.22 $45,049 - $63,692	2,257 Added 2.16%	106,964 $2.71 Million
Q3 2022 Nov 09, 2022	SELL	$18.26 - $31.1 $17,493 - $29,793	-958 Reduced 0.91%	104,707 $2.02 Million
Q2 2022 Aug 09, 2022	BUY	$19.08 - $26.7 $10,245 - $14,337	537 Added 0.51%	105,665 $2.69 Million
Q1 2022 May 11, 2022	BUY	$21.19 - $40.01 $2.23 Million - $4.21 Million	105,128 New	105,128 $2.7 Million
Q2 2021 Aug 13, 2021	SELL	$38.75 - $51.0 $780,890 - $1.03 Million	-20,152 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$26.34 - $83.07 $878,043 - $2.77 Million	-33,335 Reduced 62.32%	20,152 $1.03 Million
Q4 2020 Feb 12, 2021	BUY	$25.51 - $43.38 $452,572 - $769,604	17,741 Added 49.63%	53,487 $1.43 Million
Q3 2020 Nov 12, 2020	BUY	$28.28 - $53.6 $1.01 Million - $1.92 Million	35,746 New	35,746 $1.23 Million

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $944M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.